Verona Pharma, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa
Clinical trials sponsored by Verona Pharma, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa, explained in plain language.
-
New combo inhaler aims to improve breathing in COPD patients
Disease control Recruiting nowThis study tests a new fixed-dose combination of two drugs (ensifentrine and glycopyrrolate) given twice daily via nebulizer in 480 adults with COPD. The goal is to see if the combination improves lung function more than either drug alone or placebo. Participants will be randomly…
Phase: PHASE2 • Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA • Aim: Disease control
Last updated May 16, 2026 23:49 UTC
-
New inhaler aims to cut dangerous lung infections in bronchiectasis patients
Disease control Recruiting nowThis study tests an inhaled drug called ensifentrine in people with non-cystic fibrosis bronchiectasis, a lung condition that causes repeated infections and breathing trouble. About 284 adults will receive either the drug or a placebo twice daily for at least 24 weeks. The main g…
Phase: PHASE2 • Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
New inhaled drug shows promise in calming COPD lung inflammation
Disease control Recruiting nowThis study tests an inhaled drug called ensifentrine in 56 adults with COPD, a chronic lung disease. Participants will receive both the drug and a placebo at different times to see if the drug reduces inflammation in the lungs. The goal is to find a new way to control COPD sympto…
Phase: PHASE2 • Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA • Aim: Disease control
Last updated May 12, 2026 13:43 UTC